Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Brand Name | Status | Last Update |
---|---|---|
erivedge | New Drug Application | 2024-12-02 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
skin neoplasms | EFO_0004198 | D012878 | C44 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 4 | 6 | — | — | 1 | 11 |
Basal cell carcinoma | D002280 | — | — | 2 | 6 | — | — | 1 | 9 |
Basal cell neoplasms | D018295 | — | — | 2 | 5 | — | — | 1 | 8 |
Neoplasms | D009369 | — | C80 | 2 | 2 | — | — | — | 4 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 2 | — | — | — | 3 |
Basal cell nevus syndrome | D001478 | EFO_0004136 | — | 1 | 2 | — | — | — | 3 |
Colorectal neoplasms | D015179 | — | — | — | 2 | — | — | — | 2 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
Syndrome | D013577 | — | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | — | 1 |
Drug common name | Vismodegib |
INN | vismodegib |
Description | Vismodegib is a benzamide obtained by formal condensation between the carboxy group of 2-chloro-4-(methylsulfonyl)benzoic acid and the anilino group of 4-chloro-3-(pyridin-2-yl)aniline. Used for the treatment metastatic basal cell carcinoma. It has a role as an antineoplastic agent, a SMO receptor antagonist, a Hedgehog signaling pathway inhibitor and a teratogenic agent. It is a sulfone, a member of benzamides, a member of pyridines and a member of monochlorobenzenes. |
Classification | Small molecule |
Drug class | hedgehog signaling inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1 |
PDB | — |
CAS-ID | 879085-55-9 |
RxCUI | — |
ChEMBL ID | CHEMBL473417 |
ChEBI ID | 66903 |
PubChem CID | 24776445 |
DrugBank | DB08828 |
UNII ID | 25X868M3DS (ChemIDplus, GSRS) |